Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

(2016) Sheena Kayaniyil et al.   Diabetes Therapy

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

(2016) Sheena Kayaniyil et al.   Diabetes Therapy

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States

(2015) Bruce Wang et al.   PLoS One

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

(2015) Scott D. Ramsey et al.   VALUE IN HEALTH

The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes

(2014) S. Lane et al.   CURRENT MEDICAL RESEARCH AND OPINION

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82

(2013) A. J. Hayes et al.   DIABETOLOGIA

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

(2013) Michael Grimm et al.   POSTGRADUATE MEDICINE

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2in Spain

(2013) Tiago Fonseca et al.   JOURNAL OF MEDICAL ECONOMICS

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

(2012) D. A. Scott et al.   DIABETES OBESITY & METABOLISM

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

(2012) N. Hex et al.   DIABETIC MEDICINE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

(2012) Yevgeniy Samyshkin et al.   JOURNAL OF MEDICAL ECONOMICS

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

(2012) Anne-Laure Guillermin et al.   JOURNAL OF MEDICAL ECONOMICS

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden

(2011) Ola Granström et al.   Primary Care Diabetes

Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

(2011) Amélie Beaudet et al.   JOURNAL OF MEDICAL ECONOMICS

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

(2010) P. McEwan et al.   DIABETES OBESITY & METABOLISM

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

(2009) Michael Drummond et al.   VALUE IN HEALTH

Costs of managing severe hypoglycaemia in three European countries

(2009) Mette Hammer et al.   JOURNAL OF MEDICAL ECONOMICS

The cost of renal dialysis in a UK setting--a multicentre study

(2008) K. Baboolal et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION